BioInnovation Institute Fonden
Core data
Name | BioInnovation Institute Fonden |
Address | Ole Maaløes Vej 3, 2200, København N |
Founded | Dec 1, 2020 |
| 130 / 115 | |
Locations (P-units) | 1View locations |
Website | https://www.bioinnovationinstitute.com/ |
Branch | Trusters aktiviteter (643200) |
Name | BioInnovation Institute Fonden |
Address | Ole Maaløes Vej 3, 2200, København N |
Founded | Dec 1, 2020 |
| 130 / 115 |
Locations (P-units) | 1View locations |
Website | https://www.bioinnovationinstitute.com/ |
Branch | Trusters aktiviteter (643200) |
Keep track of BioInnovation Institute Fonden
Description
BioInnovation Institute Fonden is a commercial foundation with a charitable purpose: to own and operate the BioInnovation Institute and promote research, innovation and entrepreneurship in biotechnology and life science, including by funding and supporting the development of inventions, discoveries and companies. The 2025 accounts show a net profit of DKK 191.7 million, compared with DKK 448.8 million in 2024; equity was DKK 738.3 million at the end of 2025, against DKK 807.7 million a year earlier. The 2024 comparison is the corrected figure in the 2025 accounts. In August 2026, the foundation had 130 employees and 115 full-time equivalents; in August 2025, it had 116 employees and 105 full-time equivalents. The foundation currently owns 100% of BII Holdings A/S and Deep Tech Lab A/S. BII Holdings A/S currently owns 100% of ACCELERACE MANAGEMENT A/S and 50–66.66% of BII Catalyst AIFM ApS; its voting rights in BII Catalyst AIFM ApS are 90%.
Company's own description on virk.dk
The objectives of the FoundationThe objectives of the BioInnovation Institute Fonden (BII) are with a charitable aim to own and operate the BioInnovationInstitute and to promote research, innovation and entrepreneurship for the benefit of people and society by funding andsupporting the development of inventions, discoveries and companies operating within deep tech and life science, thusproviding a basis for growth and creation of new jobs within biotechnology and life science. The Foundation can also support other charitable scientific purposes within biotechnology and life science.
Analysis by AI ✨
The 2025 accounts show a net profit of DKK 191.7 million, compared with DKK 448.8 million in 2024; equity was DKK 738.3 million at the end of 2025, against DKK 807.7 million a year earlier. The 2024 comparison is the corrected figure in the 2025 accounts.
In August 2026, the foundation had 130 employees and 115 full-time equivalents. In August 2025, the figures were 116 employees and 105 full-time equivalents, respectively.
The foundation currently owns 100% of BII Holdings A/S and Deep Tech Lab A/S. BII Holdings A/S currently owns 100% of ACCELERACE MANAGEMENT A/S and 50–66.66% of BII Catalyst AIFM ApS; its voting rights in BII Catalyst AIFM ApS are 90%.
AI-generated texts are based on registered information, which may be delayed or incomplete. Errors may occur.
Financials
| Reporting period | 2025DKK | |||||
|---|---|---|---|---|---|---|
| Revenue | 124,523,000 | |||||
| Gross profit | 340,316,000 | |||||
| Operating profit | 192,858,000 | |||||
| Profit before tax | 195,761,000 | |||||
| Net income | 0 | |||||
| Total assets | 901,047,000 | |||||
| Equity | 738,322,000 | |||||
| Avg. employees | 126 | |||||
2020–2025 Unlock financial history | ||||||
Datapublica Risk Score
What goes into the assessment
Financials
Equity ratio, profitability, and liquidity
Accounts and history
Late filings and previous financial distress
Owners and management
Past bankruptcies and owners’ other companies
Company and connections
Age, industry, and shared addresses or contact details
Standard: Score and risk bandPro: Also a detailed explanation of the factors
Contact
No contact details have been registered for this company.
Gazelle
2 consecutive growth years
Børsen Gazelle is Dagbladet Børsen's award. Datapublica is not affiliated with Børsen. Calculated statuses are Datapublica's own analysis of public CVR financial-statement data.
People
| Person | Roles | Titles |
|---|---|---|
| Mads Krogsgaard Thomsen | Roles Board | TitlesBESTYRELSESMEDLEM |
| Marianne Philip | Roles Board | TitlesFORMAND |
| Martin Bonde | Roles Board | TitlesBESTYRELSESMEDLEM |
| Jens Bredal Nielsen | Roles Management | TitlesADM. DIR. |
Auditor
| Audit firm | Auditor | Role | From |
|---|---|---|---|
| PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab | AuditorElife Savas | RoleState Authorised Public Accountant | FromMar 24, 2026 |
| PricewaterhouseCoopersStatsautoriseret Revisionspartnerselskab | AuditorTue Stensgård Sørensen | RoleState Authorised Public Accountant | FromMar 24, 2026 |
Child companies
| Company | Ownership | Voting rights | From |
|---|---|---|---|
| Ownership100 % | Voting rights100 % | FromJan 1, 2021 | |
| Ownership100 % | Voting rights100 % | FromMay 10, 2023 | |
| Ownership15–19.99 % | Voting rights15 % | FromJun 30, 2026 | |
| Ownership10–14.99 % | Voting rights10 % | FromJun 29, 2026 | |
| Ownership5–9.99 % | Voting rights5 % | FromOct 14, 2025 |
Indirectly owned companies
| Name | Ownership through | Calculated ownership |
|---|---|---|
| Accelerace Invest II Komp. ApS | Ownership through | 100 % |
| ACCELERACE MANAGEMENT A/S | Ownership through | 100 % |
| BII Catalyst AIFM ApS | Ownership through | 50–66.66 % |
| Kommanditselskabet af 1. marts 2025 | Ownership through | 50–66.66 % |
| Komplementarselskabet af 26. februar 2025 ApS | Ownership through | 50–66.66 % |
| ACCELERACE INVEST K/S | Ownership through | 33.33–49.99 % |
| Progression Ventures ApS | Ownership through | 33.33–49.99 % |
| ACCELERACE INVEST MANAGEMENT ApS | Ownership through | 25–33.32 % |
| iNotify ApS | Ownership through | 15–19.99 % |
| Agrobiomics ApS | Ownership through | 10–14.99 % |
| Cambiotics ApS | Ownership through | 10–14.99 % |
| Udviklingsselskabet af 28. oktober 2025 ApS | Ownership through | 10–14.99 % |
| EvodiaBio ApS | Ownership through | 5–9.99 % |
| Pura Futura A/S | Ownership through | 5–9.99 % |
| Pura Futura TopCo Holding ApS | Ownership through | 5–9.99 % |
| UNIKUM Therapeutics ApS | Ownership through | 5–9.99 % |
| Nysted CCUS ApS | Ownership through | 2.5–6.66 % |